coagulation factor IX
Última actualización 10 de abril de 2023
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Ask Patient
- Versión en audio
- Agregar a fuentes preferidas en Google
El F9 gene provides instructions for making a protein called coagulation factor IX. Coagulation factors are a group of related proteins that are essential for the formation of blood clots. After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Selecciones de videos para GenesBiblioteca de videos
Normal function
El F9 gene provides instructions for making a protein called coagulation factor IX. Coagulation factors are a group of related proteins that are essential for the formation of blood clots. After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Coagulation factor IX is made in the liver. This protein circulates in the bloodstream in an inactive form until an injury that damages blood vessels occurs. In response to injury, coagulation factor IX is activated by another coagulation factor called factor XIa. The active protein (sometimes written as coagulation factor IXa) interacts with coagulation factor VIII and other molecules. These interactions set off a chain of additional chemical reactions that form a blood clot.
Conditions referring to this gene or chromosome
Otros nombres
Christmas factor
coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)
FA9_HUMAN
Factor 9
FIX
HEMB
Plasma thromboplastin component
PTC
Related patient information and medicines

Patient information leaflet
Hemofilia
Haemophilia is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platele... Haemophilia is a rare bleeding disorder caused by deficiency of clotting factors. Clotting factors are present in the blood and are responsible for forming blood clots in response to an.

Patient information leaflet
Pruebas de coagulación sanguínea
Pruebas de coagulación sanguínea are used to diagnose and assess bleeding problems and to monitor people who take warfarina u otro anticoagulante medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. These chemicals then react with other chemicals and proteins in th... There are 13 known clotting factors which.

Patient information leaflet
esófago de Barrett
Nearby normal cells then multiply and... Argon plasma coagulation This treatment uses a jet de argon gas, together with an electric current, to burn away dysplastic cells. Endoscopic mucosal resection (EMR) This is a procedure that is done via instruments passed down the side of a gastroscope. Balloon cryotherapy The National Institute for Health.

Patient information leaflet
Trombofilia
The body has a natural clotting process in the blood, which is altered in thrombophilia. What is thrombophilia. Thrombophilia refers to a group of conditions where the blood clots more easily than normal. This can lead to unwanted blood clots (called thromboses) forming within blood vessels. These blood clots can cause problems such as deep vein.

Patient information leaflet
Anticoagulantes
The clo. However, some people get problems when blood clots form at the wrong time, or in the wrong places. These activated platelets and the damaged tissue release chemicals which react with other chemicals and proteins in the blood, called clotting factors. There are 13 known clotting factors which are called by their Roman numbers - factor I to.

Patient information leaflet
Tromboflebitis superficial
Superficial thrombophlebitis is inflammation of a vein just under the skin, usually in the leg. A small blood clot also commonly forms in the vein, but is usuall... Hirudoid® cream (heparinoid) may improve your symptoms, although there is some evidence that heparin gel may be more effective. Fondaparinux (also called Arixtra®) is an injected.
Lecturas adicionales y referencias
- coagulation factor IX; MedlinePlus, National Library of Medicine.
- Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003 May 24;361(9371):1801-9. doi: 10.1016/S0140-6736(03)13405-8.
- Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol. 2002 Apr;55(2):127-44. doi: 10.1136/mp.55.2.127.
- Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest. 1996 Oct 1;98(7):1619-25. doi: 10.1172/JCI118956.
- Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24. doi: 10.1517/14656566.6.9.1517.
- Kristensen SR. Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity. Blood. 2002 Oct 1;100(7):2676-7. doi: 10.1182/blood-2002-06-1753. No abstract available.
- Lillicrap D. The molecular basis of haemophilia B. Haemophilia. 1998 Jul;4(4):350-7. doi: 10.1046/j.1365-2516.1998.440350.x.
- Oldenburg J, Kriz K, Wuillemin WA, Maly FE, von Felten A, Siegemund A, Keeling DM, Baker P, Chu K, Konkle BA, Lammle B, Albert T; Study Group on Hereditary Warfarin Sensitivity. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost. 2001 Mar;85(3):454-7.
- Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Muller CR, Hertfelder HJ, Schwaab R, Brackmann HH, Hanfland P. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol. 1997 Jul;98(1):240-4. doi: 10.1046/j.1365-2141.1997.2213036.x.
- Ulrich S, Brand B, Speich R, Oldenburg J, Asmis L. Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland. Swiss Med Wkly. 2008 Feb 23;138(7-8):100-7. doi: 10.4414/smw.2008.12022.
- Zogg T, Brandstetter H. Activation mechanisms of coagulation factor IX. Biol Chem. 2009 May-Jun;390(5-6):391-400. doi: 10.1515/BC.2009.057.
Historial del artículo
Artículo también disponible en Inglés, Alemán, Español, Francés, Italiano, Portugués, Hindi, Hebreo, Árabe, y Sueco.
10 de abril de 2023 | Última versión
1 May 2010 | Publicado originalmente
Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.
Suscríbete al boletín de Patient
Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.

